1. In vitro activity of isavuconazole against three species of Acanthamoeba.
- Author
-
Brunet K, Eestermans R, Rodier MH, and Cateau E
- Subjects
- Acanthamoeba classification, Acanthamoeba growth & development, Acanthamoeba physiology, Acanthamoeba Keratitis drug therapy, Acanthamoeba castellanii drug effects, Acanthamoeba castellanii growth & development, Acanthamoeba castellanii physiology, Animals, Dose-Response Relationship, Drug, Humans, Nitriles therapeutic use, Parasite Encystment drug effects, Parasitic Sensitivity Tests, Pyridines therapeutic use, Triazoles therapeutic use, Trophozoites drug effects, Acanthamoeba drug effects, Acanthamoeba Keratitis parasitology, Nitriles pharmacology, Pyridines pharmacology, Triazoles pharmacology
- Abstract
Acanthamoeba keratitis due to a genus of free-living amoebae is a severe corneal infection. Treatment of this disease is based on the combined use of antiseptics and other drugs, including azoles. We tested isavuconazole, the latest marketed azole, in vitro, against A. castellanii, A. lenticulata and A. hatchetti. Our results show that isavuconazole presents slight amoebistatic activity against A. castellanii trophozoites but no cysticidal activity. Isavuconazole could be used only in association for management of AK due to A. castellanii., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF